Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076388 · ClinicalTrials.gov registry record · Phase 3
Iressa Versus Docetaxel (Taxotere)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,440
- Enrollment target
NCT00076388 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 1,440 participants.
The verdict
NCT00076388, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,440 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effects of ZD1839 or docetaxel in patients with advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based chemotherapy.
Interventions
- DRUG Docetaxel
- DRUG Gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,440 participants |
| Start Date | 2004-02 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00076388
The ClinicalTrials.gov registry entry for NCT00076388 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,440 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00076388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00076388 about?
NCT00076388 is a clinical study titled "Iressa Versus Docetaxel (Taxotere)". The purpose of this study is to compare the effects of ZD1839 or docetaxel in patients with advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based chemotherapy.
What is the current status of trial NCT00076388?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,440 participants. The study started on 2004-02. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00076388?
The interventions under investigation include: Docetaxel (DRUG), Gefitinib (DRUG).
Who is sponsoring clinical trial NCT00076388?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.